# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-26
**æ›´æ–°æ—¶é—´**: 2026-01-27 03:46
**æ–°é—»æ•°é‡**: 105

---

## ä»Šæ—¥æ¦‚è§ˆ

## ðŸ“Š AI æ™ºèƒ½åˆ†æž

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºŽé‡ç£…äº¤æ˜“ä¸Žå…³é”®ä¸´åºŠè¿›å±•ã€‚BioMarinä»¥48äº¿ç¾Žå…ƒæ”¶è´­Amicus Therapeuticsæˆä¸ºæœ€å¤§å¹¶è´­æ¡ˆï¼Œè€Œèµ›è¯ºè²çš„æ½œåœ¨é‡ç£…å…ç–«è¯ç‰©åœ¨æ¹¿ç–¹IIIæœŸè¯•éªŒä¸­å–å¾—ç§¯æžæ•°æ®ï¼Œä¸ºä¸Šå¸‚é“ºå¹³é“è·¯ã€‚åŒæ—¶ï¼Œè¯ºå’Œè¯ºå¾·çš„å£æœWegovyä¸Šå¸‚åˆæœŸè¡¨çŽ°å¼ºåŠ²ï¼Œæ˜¾ç¤ºå‡ºGLP-1å¸‚åœºçš„æŒç»­çƒ­åº¦ã€‚

### ðŸ”¥ é‡ç‚¹æ–°é—»

**6. Another biopharma tried buying Amicus before BioMarin's $4.8B deal** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - BioMarinä»¥48äº¿ç¾Žå…ƒæ”¶è´­Amicus Therapeuticsæ˜¯è¿‘æœŸæœ€å¤§è§„æ¨¡å¹¶è´­æ¡ˆä¹‹ä¸€ï¼Œæ­ç¤ºäº†ç½•è§ç—…é¢†åŸŸçš„æ¿€çƒˆç«žäº‰ä¸Žèµ„äº§ä»·å€¼ã€‚

**4. Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster** â­â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - èµ›è¯ºè²æ½œåœ¨é‡ç£…å…ç–«è¯ç‰©åœ¨å…³é”®æ¹¿ç–¹IIIæœŸè¯•éªŒä¸­å–å¾—æˆåŠŸï¼Œä¸ºå…¶é€’äº¤FDAç”³è¯·å¥ å®šåŸºç¡€ï¼Œæœ‰æœ›æˆä¸ºæ•°åäº¿ç¾Žå…ƒçº§äº§å“ã€‚

**11. Novo's Wegovy pill launch wows with strong early uptake: analysts** â­â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æž
   - è¯ºå’Œè¯ºå¾·å£æœWegovyä¸Šå¸‚ç¬¬äºŒå‘¨å¤„æ–¹é‡è¾¾1.84ä¸‡ï¼Œè¿œè¶…é¢„æœŸï¼Œæ ‡å¿—ç€å£æœGLP-1ç–—æ³•å•†ä¸šåŒ–å–å¾—é‡å¤§æˆåŠŸï¼Œå¯èƒ½é‡å¡‘è‚¥èƒ–ç—‡å¸‚åœºæ ¼å±€ã€‚

**27. GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - GSKä»¥22äº¿ç¾Žå…ƒæ”¶è´­RAPT Therapeuticsï¼ŒèŽ·å¾—ä¸€æ¬¾æœ‰æ½œåŠ›çš„é£Ÿç‰©è¿‡æ•æ²»ç–—è¯ç‰©ï¼Œæ˜¯å…¶åŠ å¼ºå…ç–«å­¦ç®¡çº¿çš„é‡è¦æˆ˜ç•¥ä¸¾æŽªã€‚

**14. Led by Darzalex surge, J&J expects revenue to reach $100B in 2026** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æž
   - å¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾Žå…ƒï¼Œä¸»è¦ç”±é‡ç£…æŠ—ç™Œè¯Darzalexé©±åŠ¨ï¼Œåæ˜ äº†å…¶åœ¨è‚¿ç˜¤é¢†åŸŸçš„å¼ºå¤§å¸‚åœºåœ°ä½å’Œå¢žé•¿å‰æ™¯ã€‚

### ðŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘åŠ¨æ€ç›¸å¯¹å¹³ç¨³ï¼Œä½†èµ›è¯ºè²çš„æ½œåœ¨å…ç–«å­¦é‡ç£…è¯ç‰©å’ŒRAPTçš„é£Ÿç‰©è¿‡æ•ç–—æ³•ï¼ˆè¢«GSKæ”¶è´­ï¼‰æ˜¯ç„¦ç‚¹ã€‚æ­¤å¤–ï¼ŒF2Gè®¡åˆ’åœ¨6æœˆèŽ·å¾—IIIæœŸæ•°æ®åŽé‡æ–°å‘FDAæäº¤æŠ—çœŸèŒè¯ç”³è¯·ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): ä¸´åºŠè¯•éªŒæ–¹é¢æ¶ˆæ¯å¥½åå‚åŠã€‚èµ›è¯ºè²æ¹¿ç–¹è¯ç‰©IIIæœŸæ•°æ®ç§¯æžï¼Œè€ŒBausch Healthçš„æ–°é…æ–¹Xifaxan IIIæœŸè¯•éªŒå¤±è´¥ï¼ŒGenmabåˆ™åœæ­¢äº†ä»ŽProfoundBioæ”¶è´­çš„ç™Œç—‡å€™é€‰è¯ç‰©GEN1286çš„æ—©æœŸè¯•éªŒæ‚£è€…æ‹›å‹Ÿã€‚

### ðŸ”® æ˜Žæ—¥å…³æ³¨

æ˜Žæ—¥å€¼å¾—å…³æ³¨FDA/MHRA/Health Canadaå…³äºŽè‰¯å¥½ä¸´åºŠå®žè·µã€ç”Ÿç‰©ç­‰æ•ˆæ€§å’Œè¯ç‰©è­¦æˆ’å®žè·µçš„è”åˆç ”è®¨ä¼šï¼ˆ06/02/2026ï¼‰ï¼Œå…¶è®¨è®ºå†…å®¹å¯èƒ½å½±å“æœªæ¥çš„å…¨çƒç›‘ç®¡åè°ƒä¸Žè¯ç‰©å¼€å‘æ ‡å‡†ã€‚æ­¤å¤–ï¼Œéœ€æŒç»­è·Ÿè¸ªå£æœWegovyçš„å¸‚åœºæ¸—é€çŽ‡ä»¥åŠèµ›è¯ºè²æ¹¿ç–¹è¯ç‰©çš„æ­£å¼ç›‘ç®¡æäº¤æ—¶é—´è¡¨ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 43 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## ç»¼åˆ | ç»¼åˆ

### ðŸ‡ºðŸ‡¸ Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 09:13
- **é‡è¦æ€§**: â­â­â­â­â­

> Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has lassoed up a â€œmajor partnershipâ€ with an unnamed, â€œleading innovative biopharmaceutical companyâ€ to help produce the partner's non-bacterial beta-lactam tablets.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/fda-winds-changing-recipharm-debuts-purpose-built-plant-beta-lactam-drugs)

---

### ðŸ‡ºðŸ‡¸ Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 07:36
- **é‡è¦æ€§**: â­â­â­â­

> CDMO Samsung Biologics grew sales more than 30% last year to around 4.6 trillion Korean won ($3.1 billion) and lifted its 2025 operating profit to roughly 2.07 trillion won ($1.4 billion). Samsung Bio is now the first Korean biotech or pharmaceutical company to surpass the 2 trillion won annual profit threshold, local news outlets reported this week.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/samsung-bio-sticks-landing-2025-it-becomes-first-korean-biopharma-hit-2-trillion-won-profit)

---

### ðŸ‡ºðŸ‡¸ Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:08
- **é‡è¦æ€§**: â­â­â­

> A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the companyâ€™s bread-and-butter Xifaxanâ€”a setback that leaves a $2 billion hole in its growth plan.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/bausch-healths-2b-pursuit-xifaxan-successor-hits-wall-phase-3-failure)

---

### ðŸ‡ºðŸ‡¸ CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54
- **é‡è¦æ€§**: â­â­â­

> The project, which involves Merck, SK Bioscience, Hilleman Laboratories and CDMO IDT Biologika, aims to make Merck's current Ebola vaccine easier to manufacture and store, prompting broader global accessibility.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/cepi-bankrolls-30m-ebola-vaccine-collaboration-merck-sk-biosciences-and-others)

---

### ðŸ‡ºðŸ‡¸ Novo's Wegovy pill launch wows with strong early uptake: analysts

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 09:42
- **é‡è¦æ€§**: â­â­

> In the second week of oral Wegovyâ€™s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than that of either injectable Wegovy or Eli Lilly's Zepbound during the first two weeks of their respective rollouts, the analyst team noted.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says)

---

### ðŸ‡ºðŸ‡¸ Fierce Pharma Asiaâ€”Astellas CEO's BD plan; Takeda's US layoffs; Chugai's chase for name recognition

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:31
- **é‡è¦æ€§**: â­â­

> Astellas CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. Chugai's CEO is seeking name recognition as the Roche unit looks for more external partners. And more.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/astellas-ceo-bd-plan-takeda-us-layoffs-chugai-chase-name-recognition)

---

### ðŸ‡ºðŸ‡¸ Biosimilar execs optimistic about future for US biosims as Sandoz locks in on 'golden decade' to come

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 17:07
- **é‡è¦æ€§**: â­â­

> Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade)

---

### ðŸ‡ºðŸ‡¸ Led by Darzalex surge, J&amp;J expects revenue to reach $100B in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:20
- **é‡è¦æ€§**: â­â­

> Led by cancer standout Darzalex, Johnson &amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:05
- **é‡è¦æ€§**: â­â­

> The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 14:27
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 17:40
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:14
- **é‡è¦æ€§**: â­â­

> Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 08:01
- **é‡è¦æ€§**: â­â­

> GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Arcutis, Kowa part ways on US marketing partnership for Zoryve

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 11:15
- **é‡è¦æ€§**: â­

> The companies had committed to a five-year partnership in July 2024, in which Kowa agreed to promote the topical treatment to primary care physicians to extend the med's reach beyond dermatologists.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/arcutis-kowa-cut-ties-two-years-us-marketing-partnership-arcutis-topical-zorvye)

---

### ðŸ‡ºðŸ‡¸ Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:55
- **é‡è¦æ€§**: â­

> As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials)

---

### ðŸ‡ºðŸ‡¸ Catalent moves to wind down operations at EU cell therapy manufacturing hub

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 15:01

> Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell therapy manufacturing operations in the town.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/catalent-moves-wind-down-operations-eu-cell-therapy-manufacturing-hub)

---

### ðŸ‡ºðŸ‡¸ New rules, higher stakes: Biopharma plays the long game in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 13:20

> While 2025 was dedicated to â€œunderstanding a little bit more about the rules of this game that weâ€™re playing,â€ 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said Jan. 13 at Fierce JPM Week.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/biotech/new-rules-higher-stakes-biopharma-plays-long-game-2026)

---

### ðŸ‡ºðŸ‡¸ Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 10:28

> With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. But the road to market leadership is growing more complex as the two AstraZeneca-partnered brands move into earlier lines of therapy while facing intensifying competition.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/daiichi-sankyo-navigates-complexity-success-enhertu-datroway-push-market-dominance)

---

### ðŸ‡ºðŸ‡¸ Lilly battles weight stigma in short film centering obesity conversation on health, not appearance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:52

> GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not)

---

### ðŸ‡ºðŸ‡¸ RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio shot guidance on podcast

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:19

> The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast â€œWhy Should I Trust You?â€ to answer exactly that.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/new-acip-chair-talks-established-science-polio-vaccine-uncertainty-and-individual-autonomy)

---

### ðŸ‡ºðŸ‡¸ ST Pharm inks $56M deal to produce API for a US biotech

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:15

> ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/st-pharm-inks-56m-deal-produce-apis-us-biotech)

---

### ðŸ‡ºðŸ‡¸ Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 07:18

> Plotting a challenge to Regeneronâ€™s blockbuster Eylea, Ocular Therapeutix has hired â€œa key architectâ€ of its rivalâ€™s launch to head its commercial team.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/ocular-drafts-eylea-launch-architect-lead-attack-regenerons-blockbuster)

---

### ðŸ‡ºðŸ‡¸ JPM26: Sunshine, AI and the deals that weren't

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:09

> Fierceâ€™s Zoey Becker, Angus Liu and Gabrielle Masson unpack the key topics and trends that stood out at this yearâ€™s J.P. Morgan Healthcare Conference.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/recapping-2026-jp-morgan-healthcare-conference)

---

### ðŸ‡ºðŸ‡¸ Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:19

> While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius)

---

### ðŸ‡ºðŸ‡¸ Invivyd teams up with Olympic skier Lindsey Vonn for antibody education

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54

> As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education)

---

### ðŸ‡ºðŸ‡¸ Lundbeck 'not willing to compromise' on M&amp;A strategy after missed Avadel attempt: exec

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:23

> Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that itâ€™s not desperate for deals and will not lower its standards for future M&amp;A transactions.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/lundbeck-not-willing-compromise-ma-strategy-after-missed-avadel-attempt)

---

### ðŸ‡ºðŸ‡¸ Trump's Davos drug pricing claims decried as 'fake news' by French presidency

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 09:57

> After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his tariff-tinged trade negotiations, the French presidency has pushed back against a drug pricing claim that itâ€™s branding â€œfake news.â€

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/trumps-davos-drug-pricing-claims-decried-fake-news-french-presidency)

---

### ðŸ‡ºðŸ‡¸ In J&amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 15:13

> In Johnson &amp; Johnson's long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company's defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony)

---

### ðŸ‡ºðŸ‡¸ UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:55

> Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal)

---

### ðŸ‡ºðŸ‡¸ STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 21:11

> The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Launch of Wegovy pill looks to be going strong so far

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:30

> And more biotech news brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 17:19

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Insurers blame drugmakers, hospitals for high prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 15:26

> Plus more biotech news updates, brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Health insurance execs shift blame for costly, confusing health care system

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 20:11

> Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: France rebuffs Trump over drug-pricing boast

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 15:58

> And more biotech news from The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 14:26

> Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 09:30

> Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Novo strikes deal for diabetes cell therapies

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:53

> And other biotech news, brought to you by The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Congress revives health care deal with PBM reforms

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 15:31

> This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:47

> And other biotech news brought to you by the Readout Newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:20

> U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 09:30

> In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 01:03

> Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ðŸ‡ºðŸ‡¸ Genmab halts enrollment for cancer drug from ProfoundBio buyout

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 11:31
- **é‡è¦æ€§**: â­â­â­â­â­

> Genmab has stopped enrolling patients for an early-stage trial of a cancer candidate it obtained in its $1.8 billion acquisition of US-China biotech ProfoundBio. The Phase 1/2 study of GEN1286 was meant to enroll 260 ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/)

---

### ðŸ‡ºðŸ‡¸ F2G CEO outlines biotech's FDA resubmission plans, funding and expansion

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 16:38
- **é‡è¦æ€§**: â­â­â­â­â­

> F2G plans to resubmit its antifungal to the FDA after collecting Phase 3 data this coming June, CEO Francesco Maria Lavino told Endpoints News. The biotech's oral candidate, called olorofim, was

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/f2g-ceo-outlines-biotechs-fda-resubmission-plans-funding-and-expansion/)

---

### ðŸ‡ºðŸ‡¸ Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 15:39
- **é‡è¦æ€§**: â­â­â­â­â­

> The centerpiece of Sanofiâ€™s immunology efforts succeeded in two more Phase 3 eczema studies in the US, the company announced Friday, setting up a possible FDA submission before the end of ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/)

---

### ðŸ‡ºðŸ‡¸ Another biopharma tried buying Amicus before BioMarin's $4.8B deal

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:16
- **é‡è¦æ€§**: â­â­â­â­

> The road to Amicus Therapeuticsâ€™ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs, and a months-long push to settle a ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/)

---

### ðŸ‡ºðŸ‡¸ Chinaâ€™s edge in early-stage drugmaking â€˜likely to persist,â€™ Pitchbook says

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 19:15
- **é‡è¦æ€§**: â­â­

> The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/china-biotech-drug-licensing-trends-pitchbook-cell-gene-therapy/810478/)

---

### ðŸ‡ºðŸ‡¸ Biotech investor Cormorant secures $150M for another SPAC deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 14:43
- **é‡è¦æ€§**: â­â­

> Amid a rebound in SPAC activity, the prolific &ldquo;crossover&rdquo; investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/cormorant-helix-iii-spac-deal-biotech-merger-ipo/810436/)

---

### ðŸ‡ºðŸ‡¸ Sanofi to seek approval of touted eczema drug despite mixed results

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-23 16:57
- **é‡è¦æ€§**: â­â­

> Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/sanofi-amlitelimab-eczema-atopic-dermatitis-drug-results/810353/)

---

### ðŸ‡ºðŸ‡¸ Investors load Corxel with $287M for a â€˜differentiatedâ€™ obesity pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 19:00
- **é‡è¦æ€§**: â­â­

> The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/corxel-oral-glp1-vincentage-series-d-china-deal/810242/)

---

### ðŸ‡ºðŸ‡¸ First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-24 11:00
- **é‡è¦æ€§**: â­â­

> Welcome back to another edition of Endpoints Weekly. Though we may have had a short week with Martin Luther King Jr. Day, the news kept on coming. Letâ€™s dive in. We had a little bit ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/first-movers-respond-to-herding-biomarin-vets-start-new-biotech-gsk-buys-rapt-therapeutics-and-more/)

---

### ðŸ‡ºðŸ‡¸ ACIP members depict diverging goals after schedule change

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 18:24
- **é‡è¦æ€§**: â­â­

> Fresh off health officialsâ€™ sweeping remake of the US childhood vaccine schedule, two members of a key CDC panel are depicting different versions of the committeeâ€™s work moving forward. Comments made this week by Robert ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/acip-members-depict-diverging-goals-after-schedule-change/)

---

### ðŸ‡ºðŸ‡¸ Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 12:00
- **é‡è¦æ€§**: â­â­

> â†’ Eli Lilly is one of many large pharmas that have hired displaced or disgruntled FDA officials in the past year, and Karin Bok is its latest pickup. Bok resigned in November as deputy director ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/)

---

### ðŸ‡ºðŸ‡¸ Roche boosts NC factory investment to $2B; Rentschler CEO steps down

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:39
- **é‡è¦æ€§**: â­â­

> Rocheâ€™s Genentech is topping up its investment into its Holly Springs, NC, factory to reach nearly $2 billion. The extra investment will also add an additional 100 jobs at the site ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/roche-boosts-nc-factory-investment-to-2b-rentschler-ceo-steps-down/)

---

### ðŸ‡ºðŸ‡¸ Novo climbs higher on â€˜strongâ€™ Wegovy pill launch; Terns tweaks leukemia drug deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-23 15:27
- **é‡è¦æ€§**: â­

> Novo shares have surged more than 20% amid oral Wegovy&rsquo;s fast start.&nbsp;Elsewhere, Terns opened up room for a potential partnership and Corcept solidified its case for an ovarian cancer drug.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/wegovy-pill-prescriptions-terns-deal-corcept-data-biomerieux/810253/)

---

### ðŸ‡ºðŸ‡¸ Sarepta touts three-year Duchenne gene therapy data after patient deaths

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 16:17
- **é‡è¦æ€§**: â­

> Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial. The data come after a tumultuous year ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/sarepta-touts-three-year-duchenne-gene-therapy-data-after-patient-deaths/)

---

### ðŸ‡ºðŸ‡¸ EU kicks off one-year pilot to expedite multinational trials

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 19:24
- **é‡è¦æ€§**: â­

> The European Union unveiled details of a pilot project that aims to accelerate the timeline for starting new multinational clinical trials. The voluntary pilot, called FASTâ€‘EU, will feature a maximum 10â€‘week (70â€‘day) timeline from drugmaker ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/eu-kicks-off-one-year-pilot-to-expedite-multinational-trials/)

---

### ðŸ‡ºðŸ‡¸ Sarepta, battling slowing sales, claims Duchenne gene therapyâ€™s impact grows with time

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 16:46

> On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help &ldquo;rebalance the discussion&rdquo; surrounding Elevidys.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/)

---

### ðŸ‡ºðŸ‡¸ Express Scripts considering settlement in FTC insulin price lawsuit

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 14:02

> The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/cigna-express-scripts-ftc-insulin-pricing-settlement-talks/810452/)

---

### ðŸ‡ºðŸ‡¸ The crucial role of raw material selection for success in cell therapy manufacturing

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 10:00

> &nbsp;Why raw materials make or break cell therapy manufacturing success.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/spons/the-crucial-role-of-raw-material-selection-for-success-in-cell-therapy-manu/810179/)

---

### ðŸ‡ºðŸ‡¸ From detection to prevention: How sponsored testing can transform patient outcomes

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 10:00

> Diagnostic testing has long laid the groundwork for medical decision-making. &nbsp;

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/spons/from-detection-to-prevention-how-sponsored-testing-can-transform-patient-o/809935/)

---

### ðŸ‡ºðŸ‡¸ Congress eyes tackling healthcare consolidation

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-23 14:42

> &ldquo;I think there&rsquo;s common ground here,&rdquo; one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/house-budget-committee-healthcare-affordability-consolidation/810333/)

---

### ðŸ‡ºðŸ‡¸ IRA drug pricing petitions pile up at the Supreme Court

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 20:21

> Novartis is now the sixth drugmaker to bring its Inflation Reduction Act challenge to the Supreme Court as the pharma industryâ€™s yearslong court battle comes to a head. Novartis was the last drugmaker expected to ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/)

---

### ðŸ‡ºðŸ‡¸ Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 18:32

> CytoDyn's former CEO Nader Pourhassan was sentenced Friday to 30 months in prison for misleading investors about the prospects of a potential drug and then selling his personal stock in the company at artificially inflated ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/ex-cytodyn-ceo-sentenced-to-30-months-for-pump-and-dump-scheme/)

---

### ðŸ‡ºðŸ‡¸ Catalent plans to close Belgium cell therapy site

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 17:45

> Catalent plans to close a cell therapy site in Gosselies, Belgium, due to â€œchanging market dynamics and customer needs,â€ a company spokesperson confirmed to Endpoints News. The contract developer and manufacturer is considering transitioning ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/catalent-plans-to-close-belgium-cell-therapy-site/)

---

### ðŸ‡ºðŸ‡¸ Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 15:07

> Plus, news about United Therapeutics and Fortitude Biomedicines: ðŸ—ï¸ San Diego startup licenses 'DNA construction' tech: Genyro gets exclusive rights to the technology, dubbed â€œSidewinder,â€ which was developed by researchers at ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/genyro-licences-dna-builder-from-caltech-dizal-targets-hong-kong-listing/)

---

### ðŸ‡ºðŸ‡¸ UK medicines agency seized 20M illegal drugs last year, including GLP-1s

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 12:13

> The UKâ€™s Medicines and Healthcare products Regulatory Agency (MHRA) seized almost 20 million doses of illegally traded medicines with an estimated value of nearly Â£45 million (about $61.5 million) in 2025. This is an increase ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/uk-medicines-agency-seized-20-million-illegal-drugs-last-year-including-glp-1s/)

---

### ðŸ‡ºðŸ‡¸ Novo's Wegovy pill off to a solid start after just two weeks on market

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 20:23

> Novo Nordiskâ€™s weight loss pill is off to an impressive start after less than three weeks on the market. Prescriptions are quickly ramping up, increasing by roughly 500% in the pillâ€™s second week, analysts said ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/)

---

### ðŸ‡ºðŸ‡¸ Lilly was the only pharma bidder for Ventyx

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 12:20

> Eli Lilly had very little competition in its eventual deal for Ventyx Biosciences, one of the leading drug developers in the hot NLRP3 arena. The Indianapolis drug giant scooped up the San Diego biotech for ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/lilly-was-the-only-pharma-bidder-for-ventyx/)

---

### ðŸ‡ºðŸ‡¸ Insurance CEOs defend their businesses at House hearing

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 12:10

> The CEOs of the biggest US health insurers defended their business practices before a House hearing Thursday on the soaring cost of health coverage. Republican and Democratic lawmakers slammed insurers for hiking premiums, delaying care ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/insurance-ceos-defend-their-businesses-at-house-hearing/)

---

### ðŸ‡ºðŸ‡¸ High court picked Hikmaâ€™s â€˜skinny labelâ€™ fight after letting the issue â€˜percolateâ€™

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 19:53

> Generic and brand-name drugmakers have been divided for decades over the use of â€œskinny labelsâ€ to bring lower-cost drugs to market. Now, the Supreme Court is taking up the issue. Itâ€™s wading into a case ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/high-court-picked-hikmas-skinny-label-fight-after-letting-the-issue-percolate/)

---

### ðŸ‡ºðŸ‡¸ Drugmakers spent less on Washington lobbying in 2025's final quarter

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 18:35

> The top five biopharma company spenders on congressional lobbying spent slightly less in Washington in the final quarter of 2025 than they did in the previous quarter, the latest Senate disclosures show. Pfizer and Johnson ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/drugmakers-spent-less-on-washington-lobbying-in-2025s-final-quarter/)

---

### ðŸ‡ºðŸ‡¸ Corcept's drug extends patients' lives in key ovarian cancer study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 16:08

> Corcept Therapeutics said its experimental drug cut the risk of death by 35% for patients with a challenging form of ovarian cancer when added on top of chemotherapy, notching an important win after the California ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/corcepts-drug-extends-patients-lives-in-key-ovarian-cancer-study/)

---

### ðŸ‡ºðŸ‡¸ China-founded pharma Corxel raises up to $287M for oral GLP-1

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 16:00

> Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/china-founded-pharma-corxel-raises-up-to-287m-for-oral-glp-1/)

---

### ðŸ‡ºðŸ‡¸ Health insurance CEOs head to DC

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:39

> We donâ€™t know if President Donald Trump made good on plans to meet with major health insurers yet, but their CEOs are slated to testify today before two congressional committees ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/health-insurance-ceos-head-to-dc/)

---

### ðŸ‡ºðŸ‡¸ Bristol Myers signs deal with Janux on T cell engager for $50M upfront

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:15

> Janux Therapeutics has found a new partner. The San Diego-based biotech is teaming up with Bristol Myers Squibb on a solid tumor program, but the target is not yet disclosed. Bristol ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ðŸ‡ºðŸ‡¸ Natural Disaster Preparedness and Response | Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 14:25
- **é‡è¦æ€§**: â­â­â­â­

> Stay informed on FDA's guidance for drugs used in natural disaster preparedness and response. Learn about emergency drug supplies, FDA-approved treatments, and safety measures for public health during disasters like hurricanes, floods, and more.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/emergency-preparedness-drugs/natural-disaster-preparedness-and-response-drugs)

---

### ðŸ‡ºðŸ‡¸ FDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice - 06/02/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:26
- **é‡è¦æ€§**: â­â­â­

> This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fdamhrahealth-canada-symposium-regulatory-perspectives-good-clinical-practice-bioequivalence-and)

---

### ðŸ‡ºðŸ‡¸ Patient Listening Session Summaries

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 21:44
- **é‡è¦æ€§**: â­â­

> Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries)

---

### ðŸ‡ºðŸ‡¸ Generic Drugs Program Monthly and Quarterly Activities Report

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 18:25
- **é‡è¦æ€§**: â­â­

> Monthly and quarterly metrics of the FDA Generic Drugs Program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drugs-program-monthly-and-quarterly-activities-report)

---

### ðŸ‡ºðŸ‡¸ Biosimilar Product Information

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 18:16
- **é‡è¦æ€§**: â­â­

> This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/biosimilars/biosimilar-product-information)

---

### ðŸ‡ºðŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 13:02
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ðŸ‡ºðŸ‡¸ Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 17:27
- **é‡è¦æ€§**: â­â­

> Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/pharmaceutical-quality-resources/questions-and-answers-integration-fda-facility-evaluation-and-inspection-program-human-drugs-concept)

---

### ðŸ‡ºðŸ‡¸ Registered Outsourcing Facilities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:32
- **é‡è¦æ€§**: â­â­

> Discover FDA's comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)

---

### ðŸ‡ºðŸ‡¸ Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:06
- **é‡è¦æ€§**: â­

> This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome)

---

### ðŸ‡ºðŸ‡¸ Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:04
- **é‡è¦æ€§**: â­

> This draft guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of Bayesian methods in clinical trials.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products)

---

### ðŸ‡ºðŸ‡¸ C3TI Compass (Knowledge Repository)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:46
- **é‡è¦æ€§**: â­

> Centralized knowledge repository for clinical trial innovation

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/c3ti-compass-knowledge-repository)

---

### ðŸ‡ºðŸ‡¸ Bayesian Statistical Analysis (BSA) Demonstration Project

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:45
- **é‡è¦æ€§**: â­

> C3TI aims to increase experience in Bayesian statistical methods in simple trial settings across sponsors, CDER clinical reviewers, and CDER statisticians, including deepening an understanding of their applicability, opportunities, and challenges.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/bayesian-statistical-analysis-bsa-demonstration-project)

---

### ðŸ‡ºðŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 17:41

> Generic Drug Facilities, Sites and Organization Lists

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ðŸ‡ºðŸ‡¸ Genetic Metabolic Diseases Advisory Committee (GeMDAC) Charter

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 21:18

> The Genetic Metabolic Diseases Advisory Committee (GeMDAC) advises the Commissioner of Food and Drugs or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs and biologic products for human use and as required.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/advisory-committees/genetic-metabolic-diseases-advisory-committee/genetic-metabolic-diseases-advisory-committee-gemdac-charter)

---

### ðŸ‡ºðŸ‡¸ Real-World Evidence

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 18:08

> Real-world data (RWD) and real-world evidence (RWE) played an increasing role in health care decisions. The 21st Century Cures Act, passed in 2016, placed additional focus on the use of these types of data to support regulatory decision making.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence)

---

### ðŸ‡ºðŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 18:02

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ðŸ‡ºðŸ‡¸ Office of New Drugs Custom Medical Queries (OCMQs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 17:08

> Office of New Drugs Custom Medical Queries (OCMQs) are standardized groupings of similar adverse event terms intended to assist with the identification of potential safety issues during review of adverse event data.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/development-resources/office-new-drugs-custom-medical-queries-ocmqs)

---

### ðŸ‡ºðŸ‡¸ Drug Shortages

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 16:48

> Drug Shortages Homepage

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages)

---

### ðŸ‡ºðŸ‡¸ List of Drug Master Files (DMFs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 15:41

> The list is updated quarterly.&nbsp;Changes are made to the DMF activity status, DMF type, holder name, and subject.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs)

---

### ðŸ‡ºðŸ‡¸ Novel Drug Approvals for 2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 15:35

> Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ðŸ‡ºðŸ‡¸ Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 12:05
- **é‡è¦æ€§**: â­â­

> Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/)

---

### ðŸ‡ºðŸ‡¸ ErVimmune raises 17m euros in funding to develop cancer vaccine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 14:10
- **é‡è¦æ€§**: â­â­

> The vaccine could be created as a ready-to-use product, rather than needing to be personalised

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/)

---

### ðŸ‡ºðŸ‡¸ AAX Biotech and Vascurie announce new neuro-oncology collaboration

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:41
- **é‡è¦æ€§**: â­

> The collaboration will help to advance a pipeline of antibody candidates

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/)

---

### ðŸ‡ºðŸ‡¸ Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 11:57

> Ovarian cancer is the fifth leading cause of deaths from cancer in women

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/)

---

### ðŸ‡ºðŸ‡¸ Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 12:36

> The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/)

---

### ðŸ‡ºðŸ‡¸ Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:13

> More than 71% of patients treated with Unloxcyt achieved disease control

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/)

---

### ðŸ‡ºðŸ‡¸ Peter Llewellyn-Davies

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:02

> ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/appointments/peter-llewellyn-davies/)

---

### ðŸ‡ºðŸ‡¸ Venner Shipley announces opening of new Bristol office

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:42

> The firm already has a number of offices across the UK and Europe

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-27 03:46:12*